Printed from Voxsanity (voxsanity.com.au) — NCT07464756 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Stomach Cancer
Phase 2 Stomach Cancer Trial, Recruiting
NCT07464756
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have chosen to take part voluntarily and have signed a consent form
- People aged 18 years or older
- People who have been confirmed by laboratory testing to have stomach cancer (gastric adenocarcinoma) or cancer at the junction where the stomach meets the oesophagus (certain types only — Siewert Type II and III)
- People whose cancer has been staged by CT or MRI scan as a specific advanced but localised stage (T3-4aN+M0 under a standard staging system), and where doctors consider the tumour able to be surgically removed
- People who have not yet received any cancer treatment, including surgery, radiation, chemotherapy, targeted therapy, or immunotherapy
- People who are planned to have surgery after completing the pre-surgery treatment in this trial
- People who are able to swallow tablets normally
- People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
- People with an estimated life expectancy of 12 months or more
- People whose liver, kidneys, and other organs are functioning at an adequate level (confirm with trial site)
- Women who could become pregnant must have a negative pregnancy blood test within 72 hours before starting treatment, and must agree to use highly effective contraception during the trial and for a set period after the last dose; men with partners who could become pregnant must agree to use highly effective contraception during the trial and for a set period after the last dose, and must not donate sperm during this time
Who may not be able to join:
- People whose cancer tests positive for a marker called HER2
- People whose surgery would require a chest-opening (transthoracic) surgical approach, based on the treating doctor's assessment
- People whose cancer has spread to the lining of the abdomen, or where cancer cells have been found in abdominal fluid, or whose tumour has reached a specific advanced local stage (T4b)
- People whose tumour cannot be surgically removed for any reason, or who have a medical reason preventing surgery, or who do not wish to have surgery
- People who have had, or currently have, another cancer — except for certain previously cured cancers including a specific type of skin cancer (basal cell carcinoma), or early-stage cervical or breast cancers that were treated
- People with high blood pressure that remains uncontrolled (at or above 140/90 mmHg) despite taking blood pressure medication
- People with a known allergy or sensitivity to any of the study drugs or their ingredients
- People with known bleeding or clotting disorders, whether inherited or developed (such as haemophilia, clotting problems, or low platelet counts)
- People with a known immune system deficiency, whether present from birth or acquired (such as HIV infection)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 0086-13585172066
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
3 April 2026
Est. completion
31 May 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Pathological Complete Response (pCR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.